RT Journal Article
SR Electronic
T1 Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.10.21267485
DO 10.1101/2021.12.10.21267485
A1 David J. Sullivan
A1 Kelly A. Gebo
A1 Shmuel Shoham
A1 Evan M. Bloch
A1 Bryan Lau
A1 Aarthi G. Shenoy
A1 Giselle S. Mosnaim
A1 Thomas J. Gniadek
A1 Yuriko Fukuta
A1 Bela Patel
A1 Sonya L. Heath
A1 Adam C. Levine
A1 Barry R. Meisenberg
A1 Emily S. Spivak
A1 Shweta Anjan
A1 Moises A. Huaman
A1 Janis E. Blair
A1 Judith S. Currier
A1 James H. Paxton
A1 Jonathan M. Gerber
A1 Joann R. Petrini
A1 Patrick B. Broderick
A1 William Rausch
A1 Marie Elena Cordisco
A1 Jean Hammel
A1 Benjamin Greenblatt
A1 Valerie C. Cluzet
A1 Daniel Cruser
A1 Kevin Oei
A1 Matthew Abinante
A1 Laura L. Hammitt
A1 Catherine G. Sutcliffe
A1 Donald N. Forthal
A1 Martin S. Zand
A1 Edward R. Cachay
A1 Jay S. Raval
A1 Seble G. Kassaye
A1 E. Colin Foster
A1 Michael Roth
A1 Christi E. Marshall
A1 Anusha Yarava
A1 Karen Lane
A1 Nichol A. McBee
A1 Amy L. Gawad
A1 Nicky Karlen
A1 Atika Singh
A1 Daniel E. Ford
A1 Douglas A. Jabs
A1 Lawrence J. Appel
A1 David M. Shade
A1 Stephan Ehrhardt
A1 Sheriza N. Baksh
A1 Oliver Laeyendecker
A1 Andrew Pekosz
A1 Sabra L. Klein
A1 Arturo Casadevall
A1 Aaron A.R. Tobian
A1 Daniel F. Hanley
YR 2021
UL http://medrxiv.org/content/early/2021/12/21/2021.12.10.21267485.abstract
AB BACKGROUND The efficacy of polyclonal high titer convalescent plasma to prevent serious complications of COVID-19 in outpatients with recent onset of illness is uncertain.METHODS This multicenter, double-blind randomized controlled trial compared the efficacy and safety of SARS-CoV-2 high titer convalescent plasma to placebo control plasma in symptomatic adults ≥18 years positive for SARS-CoV-2 regardless of risk factors for disease progression or vaccine status. Participants with symptom onset within 8 days were enrolled, then transfused within the subsequent day. The measured primary outcome was COVID-19-related hospitalization within 28 days of plasma transfusion. The enrollment period was June 3, 2020 to October 1, 2021.RESULTS A total of 1225 participants were randomized and 1181 transfused. In the pre-specified modified intention-to-treat analysis that excluded those not transfused, the primary endpoint occurred in 37 of 589 (6.3%) who received placebo control plasma and in 17 of 592 (2.9%) participants who received convalescent plasma (relative risk, 0.46; one-sided 95% upper bound confidence interval 0.733; P=0.004) corresponding to a 54% risk reduction. Examination with a model adjusting for covariates related to the outcome did not change the conclusions.CONCLUSION Early administration of high titer SARS-CoV-2 convalescent plasma reduced outpatient hospitalizations by more than 50%. High titer convalescent plasma is an effective early outpatient COVID-19 treatment with the advantages of low cost, wide availability, and rapid resilience to variant emergence from viral genetic drift in the face of a changing pandemic.Trial Registration ClinicalTrials.gov number, NCT04373460.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04373460Funding StatementThis study was funded principally by the U.S. Department of Defenses (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency (DHA) (contract number: W911QY2090012) with additional support from Bloomberg Philanthropies, State of Maryland, the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID)3R01AI152078-01S1, NIH National Center for Advancing Translational Sciences (NCATS) U24TR001609-S3, Division of Intramural Research NIAID NIH, Mental Wellness Foundation, Moriah Fund, Octapharma, HealthNetwork Foundation and the Shear Family Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Johns Hopkins served as the single-IRB (sIRB). For the Center for American Indian Health sites, the protocol was also independently reviewed and approved by the Navajo Nation Health Human Research Review Board and the National Indian Health Service IRB. The protocol was also approved by the Department of Defense (DoD) Human Research Protection Office (HRPO).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors